At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma.
Questions
1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05)
2. What is the role of brentuximab vedotin in the current treatment paradigm for HL? (2:10)
3. How is the role of brentuximab vedotin likely to further evolve in the treatment of HL? (3:33)
4. How can immune checkpoint inhibitors best fit into the treatment paradigm for HL? (4:45)
5. What emerging therapeutic options seem most promising in the future treatment of HL? (5.30)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
